Bipolar Disorders and Valproate: Pharmacokinetics, Pharmacodynamics, Therapeutic Effects and Indications of Valproate: Review of Articles

  title={Bipolar Disorders and Valproate: Pharmacokinetics, Pharmacodynamics, Therapeutic Effects and Indications of Valproate: Review of Articles},
  author={Getinet Ayano},
  journal={Bipolar Disorders},
  • G. Ayano
  • Published 2016
  • Medicine, Psychology
  • Bipolar Disorders
Valproate is a mood stabilizer which is approved for use in acute and maintenance mania. It is the first line drug for bipolar patients with presence rapid cycling, irritable mania, bipolar disorder with comorbid substance use disorders, severe mania with psychosis, mixed mania and secondary mania. The specific mechanism of action of valproate in stabilizing mood is unknown. It exerts effects by enhancement of brain γ-aminobutyric acid (GABA) levels via multiple actions of synthesis and… 

Tables from this paper

Hubungan Terapi Kombinasi Mood Stabilizer dan Antipsikotik dengan Kemampuan Fungsional Pasien Gangguan Afektif Bipolar di Rumah Sakit Jiwa Grhasia Yogyakarta
There was no significant association between the combination therapy group on the patient’s functional abilities and the combination mood stabilizer and antipsychotic group in January-December 2018.
The ‘collateral side’ of mood stabilizers: safety and evidence-based strategies for managing side effects
This work aimed at critically summarizing the tolerability and safety profile for each nonantipsychotic MS, providing evidence-based strategies able to manage these AEs, in order to increase clinically useful strategies which may allow clinicians enhancing adherence and therapeutic compliance.
Changes in Non-Coding RNA in Depression and Bipolar Disorder: Can They Be Used as Diagnostic or Theranostic Biomarkers?
The evidence supporting the involvement of non-coding RNA in MDD and BD and their potential use as biomarkers for treatment response is focused on.
Open Trial of the Addition of Divalproex Sodium for Improving the Symptoms of Batak and Non-Batak Males with Schizophrenia in North Sumatra, Indonesia
There were no sign oferences in the PANSS scores between males with schizophrenia from Batak and non-Batak tribes who received risperidone monotherapy or combined with divalproex sodium.
Psychotropic drug utilization in Serdang Hospital increased markedly over the study period, with a significant increase by 859.2 % from 2008 to 2018.
Drugs-Inducing Hepatotoxicity
This review will help researchers to understand the hepatotoxicity mechanism of common drugs that have a hepatotoxic effect and result in liver transplantation or death.
Rocuronium as Selective Local Musclerelaxant in Orthopedic Surgery
The results obtained allowed us to assess the importance of knowing the pre- and post-operative history of the patient’s sedation as a source of uncertainty in the design of future treatment plans.
miRNAs as potential diagnostic biomarkers and pharmacogenomic indicators in psychiatric disorders.
An overview of circulating miRNAs and their expression profiles as biomarkers in schizophrenia, bipolar disorder and major depressive disorder and their role in response to specific treatments is provided.


Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy.
Comparative trials and extensive clinical experience have demonstrated the efficacy and tolerability of valproic acid and support its role as a valuable and well established first-line treatment for patients with a broad range of seizure types.
Therapeutic Potential of Mood Stabilizers Lithium and Valproic Acid: Beyond Bipolar Disorder
Preclinical findings have shown that the neuroprotective benefits of these agents facilitate anti-inflammation, angiogenesis, neurogenesis, blood-brain barrier integrity, and disease-specific neuroprotection, which can be compared with dysregulated disease mechanisms to suggest core cellular and molecular disturbances identifiable by specific risk biomarkers.
Science review: Carnitine in the treatment of valproic acid-induced toxicity – what is the evidence?
Carnitine supplementation during VPA therapy in high-risk patients is now recommended by some scientific committees and textbooks, especially paediatricians, and may also be valuable in those patients who develop VHT or VHE.
Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy.
  • C. M. Mock, Kristen H Schwetschenau
  • Medicine
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2012
There is more literature supporting the use of levocarnitine in VHE associated with acute overdose than with short- or long-term treatment with usual dosages of valproic acid, and levocaritine appears to be safe in the treatment of VHE.
Extracorporeal elimination in acute valproic acid poisoning
Hemmodialysis appears to be the extracorporeal method of choice to enhance VPA elimination in acute poisoning and should be considered in patients with features of severe VPA poisoning and plasma VPA concentration >850 mg/L, particularly if severe hyperammonemia and electrolyte and acid–base disturbances are present.
Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications.
There are a number of clinically relevant pharmacodynamic and pharmacokinetic differences among these medications, and these differences are discussed.
Valproic acid, a molecular lead to multiple regulatory pathways.
Data show that valproic acid affects cell growth, differentiation, apoptosis and immunogenicity of cultured cancer cells and tumours, and is emerging as a potential anticancer drug.
Polycystic ovary syndrome in women using valproate: A review
  • L. Bilo, R. Meo
  • Medicine, Psychology
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2008
Gynecologists must be aware of the possibility that PCOS in these populations of patients might be related to VPA use, and a careful multi-specialist approach is required for evaluating the risks and benefits of this treatment in the presence of features of PCOS.
Serum Valproate Levels with Oral Contraceptive Use
The introduction of OCPs was associated with increased seizure frequency or recurrence of seizures in most of the cases, and the possibility of a similar relation between VPA and OCP use is raised by the following case.
Divalproex sodium increases plasma GABA levels in healthy volunteers
The results suggest that DVP enhances GABA activity in humans, and further treatment studies of DVP on GABA function in patients with psychiatric disorders are needed to explore the significance of the enhancing effect of D VP on GABA activity.